In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial

Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4(+) T cells from HIV-1(+) individuals on suppressive...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosás-Umbert, Miriam, Ruiz-Riol, Marta, Fernández, Marco A., Marszalek, Marta, Coll, Pep, Manzardo, Christian, Cedeño, Samandhy, Miró, José M., Clotet, Bonaventura, Hanke, Tomáš, Moltó, José, Mothe, Beatriz, Brander, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100631/
https://www.ncbi.nlm.nih.gov/pubmed/32265913
http://dx.doi.org/10.3389/fimmu.2020.00418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100631/
https://www.ncbi.nlm.nih.gov/pubmed/32265913
http://dx.doi.org/10.3389/fimmu.2020.00418

Ejemplares similares